{"a":[{"_":"Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data","$":{"href":"/biotech/novo-ceo-accepts-couple-setbacks-rd-cagrisema-posts-more-mixed-data","hreflang":"en"}}]}

Data ReadoutMixedCagriSemaziltivekimabNegative

AI Analysis

Summary

Novo Nordisk's CEO acknowledged recent setbacks in R&D following mixed clinical data for CagriSema and cardiovascular candidate ziltivekimab. The company is actively pursuing bolt-on acquisitions despite these setbacks.

Outcome Details

CagriSema and ziltivekimab posted mixed data

Importance:5/10

Sentiment:

-0.40

R&D setbackmixed dataM&A interest

Related Companies

$NVO

Read the original article

Published by FierceBiotech on August 5, 2026 3:40 AM

Read Original